FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used for treating hyperproliferative disorders. That is ensured by administering a therapeutic combination in the form of a combination composition or alternatively in a mammal. The therapeutic combination comprises Trastuzumab-MCC-DMl and a chemotherapeutic compound specified in GDC-0941 and GNE-390. A pharmaceutical composition for treating a hyperproliferative disorder contains Trastuzumab-MCC-DMl and the chemotherapeutic compound specified in GDC-0941 and GNE-390.
EFFECT: group of inventions provides the synergetic effect of administering the therapeutic combination: the antibody drug conjugate of Trastuzumab-MCC-DMl and the chemotherapeutic compounds GDC-0941 and GNE-390.
16 cl, 40 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TARGETED EXPOSURE TO TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER BY HER3-TARGETED NANOPARTICLES | 2015 |
|
RU2692104C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
